We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Adapttech aim to reduce the number of sessions needed to adjust a prosthetic to it’s owner, making prosthetics more comfortable at a much faster rate. Their technology uses a laser scanner combined wearale sensors to determine where the socket needs adjustments.
days to go: Expired investment: £1,225,000
End-to-end platform that enables content owners to profitably deliver video content direct-2-user in a complex multi-device world.
days to go: Expired investment: £510,000
Alvant is a British advanced materials technology group that specialises in the design, development, testing and manufacture of Aluminium Metal Matrix Composite materials and components (AMCs). These components are demanded the engineering applications across a wide range of industry sectors. Till now, they have invested £10 million for the development, prototyping & testing AMC materials with several projects secured with distinguished clients such as Ford & Safran. Alvant has seen new advances in current customer projects and applications. Space - Tesla, Design for Demise(D4D), Bauer Hockey are some examples. With the proceeds, the company will accelerate commercialisation and growth at the rate its customers are presently demanding.
days to go: Expired investment: Withheld
A purpose-focused digital nutrition brand with a goal to enhance amino acids' impact worldwide, aiming to transform human health and performance; Having sold over 10,000 units to customers across 30+ countries, generating a monthly revenue of £27,000; Successfully raised £270,000 in funding, achieving overfunding with EIS approval and activating a £300,000 growth loan through FSE Group, further supported by the founder's personal guarantee of £150,000 due to strong confidence in success. Experience the next level of amino acid products with a delightful twist - No more struggling with water binding and bitterness. Through innovative methods, we've introduced the market's first enjoyable amino acid drink.
days to go: Expired investment: £275,000
AMUTRI LTD specializes in quick 3D visualization through CAD and BIM files. They are committed to creating the largest database of design data, tackling the difficulty of acquiring elusive building and product design information. This data plays a crucial role in driving innovations like AI-powered design, robot training, and gaming asset generation. Moreover, the company aims to address the time-consuming tasks carried out by 3D Visualisers and Artists.
days to go: Expired investment: £500,000
Ancon is designed to detect trace elements of things such as explosives, drugs and chemical weapons in the air. Ancon manufactures equipment and components that are up to 10,000 times more sensitive then anything else on the market.
days to go: Expired investment: £1,043,525
Ancon manufacture equipment and components that detect trace elements of explosives, drugs and chemical weapons in the air. Ancons technology is roughly 10,000 times more sensitive than anything currently on the market.
days to go: Expired investment: £1,043,525
Ancon technologies manufacture equipment and components to detect trace elements in the air, things such as explosives, drugs and chemical weapons. The technology created by Ancon is around 10,000x more sensitive than anything on the market at the moment. 
days to go: Expired investment: £457,000
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Antikor is developing a new cancer treatment using antibody fragment drug conjugate which penetrates solid tumours to destroy cancer cells. Their new treatment only targets pre-determined cancer cells, so healthy cells are not affected.  Biopharma is predicted to become the core of the pharmaceutical industry after undergoing transformation in the laboratory, technology and operations  
days to go: Expired investment: £125,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph